Pharmagreen Biotech (Pharmagreen Biotech) EBIT : $-0.41 Mil (TTM As of Jun. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Pharmagreen Biotech EBIT?

Pharmagreen Biotech's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2023 was $-0.14 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.41 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Pharmagreen Biotech's annualized ROC % for the quarter that ended in Jun. 2023 was -49.52%. Pharmagreen Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Pharmagreen Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -40.87%.

Pharmagreen Biotech EBIT Historical Data

The historical data trend for Pharmagreen Biotech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmagreen Biotech EBIT Chart

Pharmagreen Biotech Annual Data

Trend

Apr08

Apr09

Sep18

Sep19

Sep20

Sep21

Sep22

EBIT

Get a 7-Day Free Trial

-1.07

-0.76

-1.81

-3.76

-0.83

Pharmagreen Biotech Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
EBIT	Get a 7-Day Free Trial															0.27	-0.11	-0.02	-0.14	-0.14

Competitive Comparison of Pharmagreen Biotech's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmagreen Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmagreen Biotech's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pharmagreen Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Pharmagreen Biotech's EV-to-EBIT falls into.

Pharmagreen Biotech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.41 Mil.

Pharmagreen Biotech (OTCPK:PHBI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Pharmagreen Biotech's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

	ROC % (Q: Jun. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2023 )	+	Invested Capital (Q: Jun. 2023 ))	/ count )
=	-0.312 * ( 1 - 0% )	/	( (0.619	+	0.641)	/ 2 )
=	-0.312	/	0.63
=	-49.52 %

where

	Invested Capital		(Q: Mar. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.163	-	1.53	-	( 0.007	-	max(0, 2.06	-	0.074	+	0.007	))
=	0.619

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.14	-	1.62	-	( 0.005	-	max(0, 2.172	-	0.051	+	0.005	))
=	0.641

Note: The Operating Income data used here is four times the quarterly (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Pharmagreen Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2023		Q: Jun. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-0.572	/	( ( (0 + max(-1.69, 0))	+	(0 + max(-1.846, 0)) )	/	2 )
=	-0.572	/	( ( 0	+	0 )	/	2 )
=	-0.572	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Mar. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.001	+	0.01	+	0.056)	-	(1.53	+	0.055	+	0.172)
=	-1.69

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.001	+	0.009	+	0.036)	-	(1.62	+	0.057	+	0.215)
=	-1.846

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Pharmagreen Biotech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2023 )
	=	-0.405	/	0.991
	=	-40.87 %

Pharmagreen Biotech EBIT Related Terms

Thank you for viewing the detailed overview of Pharmagreen Biotech's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmagreen Biotech (Pharmagreen Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmagreen Biotech Inc (OTCPK:PHBI) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

112 North Curry Street, Carson, NV, USA, 89703

Website

https://www.pharmagreen.ca

Pharmagreen Biotech Inc is a biotech science company with specialized products and services in the cannabis industry. The company plans to produce and sell tissue culture plantlets and cannabis oil. Its line of nutraceutical products is a proprietary blend of therapeutic plants and mushrooms. It is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Its transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.